Immix Biopharma (IMMX) Total Liabilities (2020 - 2026)
Immix Biopharma (IMMX) posted Total Liabilities of $11.5 million for Q1 2026, up 3.69% sequentially from $11.0 million in Q4 2025, and up 11.2% YoY from $10.3 million in Q1 2025.
Immix Biopharma (IMMX) Total Liabilities (2020 - 2026) Analysis & Trends
Immix Biopharma has reported Total Liabilities for 7 years, with the latest figure at $11.5 million in Q1 2026.
- Quarterly Total Liabilities rose 11.2% year-over-year to $11.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.5 million (up 11.2% YoY) and the FY2025 annual result came in at $11.0 million, up 13.9% from the prior year.
- Total Liabilities climbed to $11.5 million in Q1 2026 per IMMX's latest filing, from $11.0 million in the prior quarter.
- Over five years, Total Liabilities peaked at $11.8 million in Q3 2025 and troughed at $365086.0 in Q1 2022.
- A 5-year average of $5.8 million and a median of $4.9 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2026: Total Liabilities jumped 765.33% in 2022, then gained 11.2% in 2026.
- Over 5 years, Total Liabilities stood at $1.7 million in 2022, then soared by 112.88% to $3.7 million in 2023, then surged by 160.54% to $9.7 million in 2024, then rose by 13.9% to $11.0 million in 2025, then climbed by 3.69% to $11.5 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $11.5 million, $11.0 million, and $11.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | 10.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.19 Mn |
| Mar 31, 2026 | 11.45 Mn |
| Dec 31, 2025 | 11.04 Mn |
| Sep 30, 2025 | 11.82 Mn |
| Jun 30, 2025 | 10.98 Mn |
| Mar 31, 2025 | 10.30 Mn |
| Dec 31, 2024 | 9.70 Mn |
| Sep 30, 2024 | 7.59 Mn |
| Jun 30, 2024 | 4.94 Mn |
| Mar 31, 2024 | 6.72 Mn |
| Dec 31, 2023 | 3.72 Mn |
| Sep 30, 2023 | 2.83 Mn |
| Jun 30, 2023 | 2.40 Mn |
| Mar 31, 2023 | 1.47 Mn |
| Dec 31, 2022 | 1.75 Mn |
| Sep 30, 2022 | 646,457.00 |
| Jun 30, 2022 | 977,209.00 |
| Mar 31, 2022 | 365,086.00 |
| Dec 31, 2021 | 202,039.00 |
| Dec 31, 2020 | 5.27 Mn |